Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.
Abnormal gene promoter methylation contributes to deregulate gene expression of hematopoietic progenitors in myelodysplastic syndromes (MDS). We analyzed the gene expression profile of myelodysplastic and normal CD34+ hematopoietic stem cells (HSCs) treated in vitro with decitabine. We identified a list of candidate tumor suppressor genes, expressed at low levels in MDS HSCs and induced by hypomethylating treatment only in MDS, but not in normal HSCs. Real-time RT-PCR confirmed reduced CD9 expression in MDS CD34+ and bone marrow mononuclear cells, compared to normal controls. CD9 was specifically up-regulated by decitabine treatment in myelodysplastic CD34+ cells.
Giachelia
Manuela
M
Institute of Hematology, Università Cattolica del Sacro Cuore, Rome, Italy.
D'Alò
Francesco
F
Fabiani
Emiliano
E
Saulnier
Nathalie
N
Di Ruscio
Annalisa
A
Guidi
Francesco
F
Hohaus
Stefan
S
Voso
Maria Teresa
MT
Leone
Giuseppe
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018952:Antigens, CD34 / Q000097:blood; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D016000:Cluster Analysis; D019175:DNA Methylation; D000077209:Decitabine; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D020869:Gene Expression Profiling; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D019012:Integrin beta1 / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D011401:Promoter Regions, Genetic / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D055815:Young Adult
D018952:Antigens, CD34; D000964:Antimetabolites, Antineoplastic; D019012:Integrin beta1; D000077209:Decitabine; D001374:Azacitidine